Clearance of Selected Plasma Cytokines with Continuous Veno-Venous Hemodialysis Using Ultraflux EMiC2 versus Ultraflux AV1000SEichhorn T.a · Hartmann J.b · Harm S.b · Linsberger I.a · König F.c · Valicek G.d · Miestinger G.d · Hörmann C.d · Weber V.a, b
aChristian Doppler Laboratory for Innovative Therapy Approaches in Sepsis, and bCenter for Biomedical Technology, Donau University Krems, Krems an der Donau, cInstitute for Medical Statistics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University Vienna, Vienna, and dUniversity Hospital St. Pölten, Department for Anaesthesiology and Intensive Care, St. Pölten, Austria
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: High cutoff hemofilters might support the restoration of immune homeostasis in systemic inflammation by depleting inflammatory mediators from the circulation. Methods: Interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor-alpha depletion was assessed in 30 sepsis patients with acute renal failure using continuous veno-venous hemodialysis with high cutoff versus standard filters (CVVHD-HCO vs. CVVHD-STD) over 48 h. Results: The transfer of IL-6 and IL-8 was significantly higher for CVVHD-HCO, as shown by increased IL-6 and IL-8 effluent concentrations. The mean plasma cytokine concentrations decreased over time for all cytokines without detectable differences for the treatment modalities. No transfer of albumin was observed for either of the filters. C-reactive protein remained stable over time and did not differ between CVVHD-HCO and CVVHD-STD, while procalcitonin decreased significantly over 48 h for both treatment modalities. Conclusion: CVVHD-HCO achieved enhanced removal of IL-6 and IL-8 as compared to CVVHD-STD, without differentially reducing plasma cytokine levels.
© 2017 S. Karger AG, Basel
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC: The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801-810.
- Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013;369:840-851.
- Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, Jaton K, Giulieri S, Delaloye J, Opal S, Tracey K, van der Poll T, Pelfrene E: Sepsis: a roadmap for future research. Lancet Infect Dis 2015;15:581-614.
- Marshall JC: Why have clinical trials in sepsis failed? Trends Mol Med 2014;20:195-203.
- Christaki E, Giamarellos-Bourboulis EJ: The beginning of personalized medicine in sepsis: small steps to a bright future. Clin Genet 2014;86:56-61.
- Marshall JC: Sepsis: rethinking the approach to clinical research. J Leukoc Biol 2008;83:471-482.
- Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-3370.
- Rimmelé T, Kellum JA: Clinical review: blood purification for sepsis. Crit Care 2011;15:205.
- Panagiotou A, Gaiao S, Cruz DN: Extracorporeal therapies in sepsis. J Intensive Care Med 2013;28:281-295.
- Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C: Cytokine removal with high cut-off membrane: review of literature. Blood Purif 2014;38:167-173.
- Vincent JL: Emerging therapies for the treatment of sepsis. Curr Opin Anaesthesiol 2015;28:411-416.
- Gentile LF, Cuenca AG, Vanzant EL, Efron PA, McKinley B, Moore F, Moldawer LL: Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods 2013;61:3-9.
- Gondouin B, Hutchison CA: High cut-off dialysis membranes: current uses and future potential. Adv Chronic Kidney Dis 2011;18:180-187.
- Boschetti-de-Fierro A, Voigt M, Storr M, Krause B: Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs 2013;36:455-463.
- Morgera S, Haase M, Rocktaschel J, Bohler T, von Heymann C, Vargas-Hein O, Krausch D, Zuckermann-Becker H, Muller JM, Kox WJ, Neumayer HH: High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003;18:2570-2576.
- Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, Krieg H, Wegner B, Bellomo R, Neumayer HH: Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-2104.
- Kade G, Lubas A, Rzeszotarska A, Korsak J, Niemczyk S: Effectiveness of high cut-off hemofilters in the removal of selected cytokines in patients during septic shock accompanied by Acute Kidney Injury-Preliminary Study. Med Sci Monit 2016;22:4338-4344.
- Chelazzi C, Villa G, D'Alfonso MG, Mancinelli P, Consales G, Berardi M, De Gaudio AR, Romagnoli S: Hemodialysis with high cut-off hemodialyzers in patients with multi-drug resistant gram-negative sepsis and acute kidney injury: a retrospective, Case-Control Study. Blood Purif 2016;42:186-193.
- Morgera S, Rocktaschel J, Haase M, Lehmann C, von Heymann C, Ziemer S, Priem F, Hocher B, Gohl H, Kox WJ, Buder HW, Neumayer HH: Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003;29:1989-1995.
- Atan R, Crosbie D, Bellomo R: Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif 2012;33:88-100.
- Atan R, Crosbie D, Bellomo R: Techniques of extracorporeal cytokine removal: a systematic review of the literature on animal experimental studies. Int J Artif Organs 2013;36:149-158.
- Mariano F, Fonsato V, Lanfranco G, Pohlmeier R, Ronco C, Triolo G, Camussi G, Tetta C, Passlick-Deetjen J: Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant 2005;20:1116-1126.
- Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
- Honoré PM, Matson JR: Extracorporeal removal for sepsis: acting at the tissue level - the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004;32:896-897.
Di Carlo JV, Alexander SR: Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005;28:777-786.
- Peng Z, Singbartl K, Simon P, Rimmele T, Bishop J, Clermont G, Kellum JA: Blood purification in sepsis: a new paradigm. Contrib Nephrol 2010;165:322-328.
- Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH: Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007;50:296-304.
- Atan R, Peck L, Visvanathan K, Skinner N, Eastwood G, Bellomo R, Storr M, Goehl H: High cut-off hemofiltration versus standard hemofiltration: effect on plasma cytokines. Int J Artif Organs 2016;39:479-486.
- Surbatovic M, Popovic N, Vojvodic D, Milosevic I, Acimovic G, Stojicic M, Veljovic M, Jevdjic J, Djordjevic D, Radakovic S: Cytokine profile in severe gram-positive and gram-negative abdominal sepsis. Sci Rep 2015;5:11355.
- Lvovschi V, Arnaud L, Parizot C, Freund Y, Juillien G, Ghillani-Dalbin P, Bouberima M, Larsen M, Riou B, Gorochov G, Hausfater P: Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study. PLoS One 2011;6:e28870.
- Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT: Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007;11:R49.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.